ANTHEM: Q1 FY27 saw lower revenue and profit sequentially, with new ESOP shares allotted
Standalone and consolidated Q1 FY27 results show sequential and year-over-year declines in revenue and profit, with CRDMO and Speciality Ingredients segments contributing to overall performance. 1.67 million shares were allotted under ESOP 2024.Original document: Anthem Biosciences Limited [ANTHEM…